Literature DB >> 10877370

Comparison of symptomatic and asymptomatic, chronic, primary angle-closure glaucoma, open-angle glaucoma, and controls.

R Sihota1, V Gupta, H C Agarwal, R M Pandey, K K Deepak.   

Abstract

PURPOSE: To determine the clinical features and anatomic parameters in asymptomatic (creeping) and symptomatic, chronic, primary angle-closure glaucoma (PACG) as compared with open-angle glaucoma (OAG) and with control subjects with normal eyes.
METHODS: Forty consecutive patients with each of the following four types of eyes were studied (N = 160): eyes with symptomatic PACG, eyes with asymptomatic PACG, eyes with OAG, and the eyes of age-, sex-, and refraction-matched control subjects. The refractive status, keratometry, pachymetry, corneal diameter, anterior chamber depth, lens thickness, axial length, and relative lens position were noted. The groups were compared using a paired t test and analysis of variance.
RESULTS: Patients with asymptomatic chronic PACG were older than patients in the symptomatic group, were more often men, and were more likely to have either diabetes mellitus or hypertension. Symptomatic chronic PACG eyes were more hypermetropic. Asymptomatic eyes had more iridotrabecular synechiae and minimal pupillary ruff atrophy as compared with the symptomatic eyes that had largely iridocorneal synechiae and large areas where the ruff was absent. All other clinical and anatomic parameters were statistically similar in the two groups, but differed significantly from OAG and control eyes.
CONCLUSIONS: The ocular parameters of asymptomatic or creeping angle closure eyes show that these are significantly different from eyes having POAG. Asymptomatic and symptomatic chronic PACG eyes are structurally similar. Open-angle glaucoma eyes and normal eyes were comparable, but differed from both the chronic angle-closure glaucoma groups in having a larger corneal diameter, deeper anterior chamber, thinner lens, and a longer axial length. The symptomatic chronic PACG eyes showed more evidence of ischemic damage to the iris, and this could account for the symptoms reported by these patients.

Entities:  

Mesh:

Year:  2000        PMID: 10877370     DOI: 10.1097/00061198-200006000-00002

Source DB:  PubMed          Journal:  J Glaucoma        ISSN: 1057-0829            Impact factor:   2.503


  7 in total

1.  Ocular biometry in occludable angles and angle closure glaucoma: a population based survey.

Authors:  R George; P G Paul; M Baskaran; S Ve Ramesh; P Raju; H Arvind; C McCarty; L Vijaya
Journal:  Br J Ophthalmol       Date:  2003-04       Impact factor: 4.638

2.  Factors affecting refractive outcome after cataract surgery in patients with a history of acute primary angle closure.

Authors:  Hyo Seok Lee; Jung Won Park; Sang Woo Park
Journal:  Jpn J Ophthalmol       Date:  2013-10-29       Impact factor: 2.447

3.  Distribution and characteristics of peripheral anterior synechiae in primary angle-closure glaucoma.

Authors:  Jong Yun Lee; Yong Yeon Kim; Hai Ryun Jung
Journal:  Korean J Ophthalmol       Date:  2006-06

4.  Effect of Visibility of the Ciliary Body Processes on Ocular Biometric Parameters in Patients with Primary Angle Closure.

Authors:  Wasu Supakontanasan; Panintorn Thunwiriya; Yanin Suwan; Suthaphat Nilphatanakorn; Sira Arunmongkol; Chaiwat Teekhasaenee
Journal:  Jpn J Ophthalmol       Date:  2019-09-14       Impact factor: 2.447

Review 5.  An Indian perspective on primary angle closure and glaucoma.

Authors:  Ramanjit Sihota
Journal:  Indian J Ophthalmol       Date:  2011-01       Impact factor: 1.848

6.  Enhancing the early differential diagnosis of plateau iris and pupillary block using a-scan ultrasonography.

Authors:  Yu-Yen Chen; Dachen Chu; Pesus Chou
Journal:  PLoS One       Date:  2015-02-17       Impact factor: 3.240

7.  Anterior segment configuration as a predictive factor for refractive outcome after cataract surgery in patients with glaucoma.

Authors:  Young Cheong Kim; Mi Sun Sung; Hwan Heo; Sang Woo Park
Journal:  BMC Ophthalmol       Date:  2016-10-18       Impact factor: 2.209

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.